La catena delle opzioni mostra i dati chiave delle opzioni azionarie di C4 Therapeutics a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per C4 Therapeutics..

C4 Therapeutics (NASDAQ:CCCC) Azioni, Catena delle Opzioni

C4 Therapeutics

C4 Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patients' lives. The Company is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. Its degrader medicines are designed to harness the body's natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, and drug undruggable targets and improve patient outcomes. Its pipeline is Cemsidomide, CFT1946, and CFT8919.

C4 Therapeutics Inc

Press Releases

Seaport Therapeutics Names Lauren White as Chief Financial Officer

PureTech Founded Entity Seaport Therapeutics Names Lauren White as Chief Financial Officer

News

Health Care

General

C4 Therapeutics to Present Data from the Ongoing Phase 1/2 Trial of Cemsidomide in Multiple Myeloma and Non-Hodgkin's Lymphoma at the American Society of Hematology (ASH) Annual Meeting

C4 Therapeutics Announces First Patient Dosed in CFT8919 Clinical Trial

Management

C4 Therapeutics Appoints Accomplished Oncology Executive Steve Hoerter to Board of Directors

C4 Therapeutics Presents Cemsidomide Phase 1 Data at the American Society for Hematology (ASH) Annual Meeting that Demonstrated Potential to Become Best-in-Class IKZF1/3 Degrader

C4 Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

C4 Therapeutics Announces 2025 Milestones Across Clinical Portfolio of Degrader Medicines Pursuing Targets of High Unmet Need in Oncology

C4 Therapeutics to Participate in Upcoming March Investor Conferences

Earnings

C4 Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights

ABBV

CCCC

IMGN

PRTC

Alector

Assembly Biosciences, Inc. - Common Stock

Assembly Biosciences

Atossa Therapeutics

Coherus BioSciences

Coya Therapeutics

Editas Medicine

Enanta Pharmaceuticals, Inc. - Common Stock

Enanta Pharma

Fate Therapeutics

Greenwich LifeSciences, Inc. - Common stock

Greenwich LifeSciences

HilleVax

Immunic

Kalaris Therapeutics, Inc. - Common Stock

Kalaris Therapeutics

Lineage Cell Therapeutics, Inc. Common Stock

Lineage Cell Therapeutics

Lyell Immunopharma

Macrogenics

ProKidney Corp. - Class A Ordinary Shares

ProKidney

Quoin Pharmaceuticals, Ltd. - American Depositary Shares

Quoin Pharmaceuticals

RAPT Therapeutics

Sera Prognostics, Inc. - Class A Common Stock

Sera Prognostics

Sagimet Biosciences Inc. - Series A Common Stock

Sagimet Biosciences

Protara Therapeutics, Inc. - Common Stock

Protara Therapeutics

Tonix Pharmaceuticals Holding Corp. - Common Stock

Tonix Pharmaceuticals

Exagen

Zentalis Pharmaceuticals, Inc. - common stock

Zentalis Pharma

Zura Bio Limited - Class A Ordinary shares

Comments

C4 Therapeutics

C4 Therapeutics (CCCC) Opzioni

C4 Therapeutics (NASDAQ:CCCC) Azioni, Catena delle Opzioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO